Functional and quality of life outcomes of localised prostate cancer treatments (Prostate Testing for Cancer and Treatment [ProtecT] study)

Abstract

ConclusionTreatment decision-making for localised prostate cancer can be informed by these 6-year functional and QoL outcomes.

Medium-term oncological outcomes of intermediate-risk prostate cancer treated with HIFU or cryotherapy. A single center 10-year experience

“…shown that active monitoring of PCa would achieve a similar overall survival as radical treatment, while enduring less treatment related side-effects (2). However, in this same cohort, Active Surveillance (AS) had a higher risk of disease progression and of metastatic disease (3).…”

Ultra-Hypofractionated Stereotactic Body Radiotherapy for Localized Prostate Cancer: Clinical Outcomes, Patterns of Recurrence, Feasibility of Definitive Salvage Treatment, and Competing Oncological Risk

“…AS should be considered as the treatment of choice for the majority of PCa patients with localized disease, as it does not compromise survival while significantly improving quality of life [ 1 , 3 ]. However, interventional methods of treatment are not exclusive but complementary, as approximately half of the patients will eventually receive active treatment [ 1 , 25 ], and some will decline AS to start off with.…”

“…However, up to 50% of diagnosed patients do not require immediate interventional treatment. Randomized clinical trials have shown that active surveillance (AS) does not compromise survival [ 1 ], while it significantly improves quality of life (QoL) and functional outcomes [ 2 , 3 ] in patients with localized disease. Current clinical guidelines recommend AS as the preferred method of treatment for patients with low-risk (LR) cancer, and as a viable option for favourable intermediate-risk group (IR) PCa [ 4 ].…”

Pre-Treatment Hemoglobin Concentration and Absolute Monocyte Count as Independent Prognostic Factors for Survival in Localized or Locally Advanced Prostate Cancer Patients Undergoing Radiotherapy

“…Unnecessary treatment of PCa patients whose life expectancy is insufficient for the treatment to have a noticeable impact on their survival can be associated with the risk of side effects and can significantly reduce the patient’s quality of life [ 23 , 24 ]. A personalized approach to the treatment of each patient requires a proper estimation of their life expectancy, especially if aggressive treatment is planned.…”